ArticleCureus2026
Maternal Serum Alpha-Fetoprotein as a Predictor of Persistent Low-Lying Placenta and Placenta Accreta Spectrum: A Prospective Observational Study.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Placenta previa and low-lying placenta are major contributors to antepartum hemorrhage and are strongly associated with placenta accreta spectrum, a leading cause of severe maternal morbidity. Early identification of pregnancies at risk remains clinically important. Maternal serum alpha-fetoprotein (MS-AFP), routinely measured during antenatal screening, has been proposed as a biomarker of abnormal placentation. This study evaluated the association between maternal serum alpha-fetoprotein levels and persistence of low-lying placenta, as well as its predictive value for placenta accreta spectrum. Methods This observational study was conducted in the Department of Obstetrics and Gynaecology, Patna Medical College and Hospital, Patna, Bihar, India. Sampling was performed using a convenience sampling approach. Consecutive eligible pregnant women attending the Department of Obstetrics and Gynaecology between November 2019 and October 2021 who fulfilled the inclusion criteria were recruited until a total of 100 participants was achieved. One hundred pregnant women with ultrasonographically confirmed low-lying placenta between 15 and 20 weeks' gestation were enrolled. Maternal serum alpha-fetoprotein levels were measured and expressed as multiples of the median. Participants were followed until delivery to assess placental migration, occurrence of placenta accreta spectrum, and obstetric outcomes. Statistical analysis was performed using appropriate comparative tests, with statistical significance defined as a p-value less than 0.05. Results Among the 100 enrolled women, low-lying placenta persisted in 45 (45.0%), whereas placental migration occurred in 55 (55.0%). Subsequent analyses demonstrated that persistence was significantly associated with prior cesarean delivery and multiparity. Placenta accreta spectrum occurred in 13 (13.0%) women, all of whom had persistent low-lying placenta. Elevated maternal serum alpha-fetoprotein levels were present in 88.9% of persistent cases and in all cases of placenta accreta spectrum. MS-AFP values greater than 1.1 MoM were associated with persistence, while MS-AFP values exceeding 1.7 MoM (multiples of the median) were strongly related with the need for cesarean hysterectomy. Conclusion MS-AFP may serve as a useful adjunctive marker for identifying pregnancies at an increased risk of persistent low-lying placenta and placenta accreta spectrum. Larger prospective studies are needed to validate these findings. These findings suggest that MS-AFP may complement ultrasonographic assessment; however, further prospective studies are required to evaluate its additional diagnostic value.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.